Last edition
News about "Strategic Shifts Amid Biosimilar Surge"
Pharma Faces $230 Billion Patent Cliff by 2030, Urging Strategic Shifts Amid Biosimilar Surge
Bristol Myers Squibb is likely to be among the hardest hit, with both Eliquis and Opdivo—major revenue contributors—set to go off-patent. GlobalData analyst George El-Helou notes that more than half of the top 15 pharma companies may struggle to absorb the impact, though some firms are leveraging promising pipeline drugs to cushion the blow.
<br />
Strategic Shifts Amid Biosimilar Surge | 07/07/2025 | By Darshana | 364
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy